Cipla Soars 4%! 🚀 Citi's 'Buy' Rating Ignites Stock Optimism
Cipla Soars 4%! 🚀 Citi's 'Buy' Rating Ignites Stock Optimism
Cipla shares jumped on Monday after Citi initiated a 'Buy' rating and 90-day Positive Catalyst Watch. US approvals, strong domestic growth, and promising valuations are driving investor confidence!
Shares of pharmaceutical major Cipla experienced a significant surge on Monday, climbing as much as 4% to reach a day's high of Rs 1,409 on the BSE. This impressive rally was triggered by international brokerage firm Citi, which placed Cipla's stock on a 90-day Positive Catalyst Watch while reiterating its 'Buy' rating.
Citi has set an ambitious target price of Rs 1,700 for Cipla, suggesting a substantial upside of 25.55% from current levels. The brokerage firm outlined several near-term factors that are expected to bolster the stock's performance. Among these are the anticipated approval of gFlovent from Cipla's Goa facility, which is poised to boost growth in the crucial US market, and the expected launch of gVentolin.
Further reinforcing the positive outlook for its US operations, Citi noted that Cipla's Nintedanib has already secured nearly 50% market share in the United States. The brokerage firmly believes that Cipla's US business is on the cusp of a revenue rebound, following a period of recent weakness. On the domestic front, Cipla continues to demonstrate robust performance, with its India business showing strong growth, particularly aided by a recovery in its respiratory portfolio.
Additional catalysts are also on the horizon. A re-inspection of Cipla's Indore plant is expected soon, and a favorable outcome, coupled with USFDA clearance, could provide another significant boost to the stock. Moreover, easing geopolitical tensions have contributed to reduced concerns regarding raw material costs and margins, further solidifying the company's financial position.
Citi analysts are optimistic that Cipla's earnings have likely bottomed out following the decline associated with gRevlimid. The stock is currently trading at 25 times its FY27E earnings and 21 times its FY28E earnings. With the India business alone contributing nearly two-thirds of the company's EBITDA, Citi highlights Cipla as an attractive investment opportunity, offering strong exposure to the thriving domestic pharmaceutical market.
